Shire PLC (SHPG)

175.23
1.21 0.70
NASDAQ : Health Care
Prev Close 174.02
Open 175.73
Day Low/High 174.04 / 175.88
52 Wk Low/High 147.60 / 270.63
Volume 758.39K
Avg Volume 1.03M
Exchange NASDAQ
Shares Outstanding 301.72M
Market Cap 52.51B
EPS 1.30
P/E Ratio 47.29
Div & Yield 1.54 (0.90%)

Latest News

European Stocks Mixed as Frankfurt Rises, Paris Falls

European Stocks Mixed as Frankfurt Rises, Paris Falls

The Dax rose following a strong performance from the automotive sector, but both London and Paris slumped.

CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] Data Demonstrate Improved Treatment Satisfaction Relative To Patients' Previous Immunoglobulin Therapy

CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] Data Demonstrate Improved Treatment Satisfaction Relative To Patients' Previous Immunoglobulin Therapy

Shire data presentations at AAAAI 2017 reinforce the efficacy, safety, and tolerability of CUVITRU for primary immunodeficiency patients

Everything We Know About BioCryst's New HAE Drug

Everything We Know About BioCryst's New HAE Drug

BioCryst's Hereditary angioedema drug-trial results not compelling.

BioCryst Pill Prevents Swelling Attacks but Shares Fall on Competitive Concerns

BioCryst Pill Prevents Swelling Attacks but Shares Fall on Competitive Concerns

Current drugs approved to prevent and reduce the frequency of HAE swelling attacks require injections, so BioCryst's once-daily pill has the potential to be more convenient.

Biotech Movers: Shire Rises on Encouraging Angioedema Results

Biotech Movers: Shire Rises on Encouraging Angioedema Results

Also up early Thursday: Bellicum and Novocure.

Shire Beats Full-Year Earnings Estimates, Sees Robust 2017 Growth

Shire Beats Full-Year Earnings Estimates, Sees Robust 2017 Growth

Shire posted full-year profits that were largely in-line with analysts' forecasts and said it could see double-digit percentage growth in 2017 earnings per share.

Biotech Buoyed by Deal Talk

Biotech Buoyed by Deal Talk

M&A activity is in a serious upswing, and here are some names to watch.

New Data From Shire Aim To Help Close The Diagnosis And Treatment Gap For People With Hemophilia

New Data From Shire Aim To Help Close The Diagnosis And Treatment Gap For People With Hemophilia

Shire presentations at EAHAD 2017 underscore the company's leadership in improving global standards of care

5 Toxic Stocks to Avoid

5 Toxic Stocks to Avoid

Here's a look at five 'toxic stocks' to sell.

Why Shire, Great Plains, GE Are Waving Red Flags

Why Shire, Great Plains, GE Are Waving Red Flags

The charts of these and two other big stocks are flashing warning signs at investors.

Drug Stocks Find Trump Animus a Bitter Pill

Drug Stocks Find Trump Animus a Bitter Pill

The president-elect's words rattled the sector, though Amgen appears to be shrugging off his remarks.

5 Things You Must Know Before the Market Opens Thursday

5 Things You Must Know Before the Market Opens Thursday

U.S. stock futures and shares in London and Asia fall Thursday after Donald Trump offers few details on his policies during his first press conference since winning the U.S. election.

European Pharma Shares Hammered After Trump Press Conference Attack

European Pharma Shares Hammered After Trump Press Conference Attack

European health care and pharmaceutical company shares were hit hard Thursday after President-elect Donald Trump accused some firms of 'getting away with murder' in his Wednesday press conference.

Allergan Unhappy with Patent Office Decision to Allow Mylan Challenge to Restasis Patents

Allergan Unhappy with Patent Office Decision to Allow Mylan Challenge to Restasis Patents

U.S. Patent Office allows Mylan to go after half a dozen patents tied to Allergan's dry eye franchise Restasis.

Amicus Tumbles on Lengthy Delay to U.S. Fabry Drug FDA Filing Plan

Amicus Tumbles on Lengthy Delay to U.S. Fabry Drug FDA Filing Plan

The U.S. Food and Drug Administration turned down Amicus' request to seek accelerated approval for Galafold based on an existing kidney biomarker data.

Actelion Soars as Johnson & Johnson 'Makes Takeover Proposal'

Actelion Soars as Johnson & Johnson 'Makes Takeover Proposal'

The Swiss biotech was last year reported to be a target of Shire.